The dysregulation score method identifies epigenetic regulator genes that predict cancer prognosis and efficiency of cancer immunotherapy
Authors:
- Jie LyuJLJie Lyu
- Hao ZhangHZHao Zhang
- Jinjin ZhongJZJinjin Zhong
- Zhen FengZFZhen Feng
Open Access
- 20 November 2025
- journal article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (4)
Abstract
No abstract availableKeywords
Funding Information
- University of Chinese Academy of Sciences
- University of the Chinese Academy of Sciences Wenzhou Institute (WIUCASQD2021006)
This publication has 72 references indexed in Scilit:
- New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communicationMedcomm, 2024
- Epigenetic regulation in cancerMedcomm, 2024
- Targeting histone deacetylases for cancer therapy: Trends and challengesActa Pharmaceutica Sinica B, 2023
- Integrated analysis of genes encoding ATP‐dependent chromatin remodellers identifies CHD7 as a potential target for colorectal cancer therapyClinical and Translational Medicine, 2022
- Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitionersCancer and Metastasis Reviews, 2021
- The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactionsProtein Science, 2020
- HDAC inhibitors overcome immunotherapy resistance in B-cell lymphomaProtein & Cell, 2020
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019
- RETRACTED: Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2AJournal of Cellular Biochemistry, 2018
- Cancer Genetics and Epigenetics: Two Sides of the Same Coin?Cancer Cell, 2012